

Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Aug-2022
Document Type: USP Monographs
DocId: GUID-D6113BEF-A38D-44F1-A69C-AFFCBB9CEFCF_4_en-US
DOI: https://doi.org/10.31003/USPNF_M52490_04_01
DOI Ref: eka19

© 2025 USPC
Do not distribute

Methylene Blue Injection

Change to read:

DEFINITION

Methylene Blue Injection is a sterile solution of Methylene Blue in Water for Injection. It contains NLT 95.0% and NMT 105.0% of the labeled amount of methylene blue ▲trihydrate▲ (USP 1-Aug-2022) ($C_{16}H_{18}ClN_3S \cdot 3H_2O$).

IDENTIFICATION

- **A.** The UV absorption spectra of the major peak of the *Sample solution* exhibit maxima and minima at the same wavelengths as those of the corresponding peak of the *Standard solution*, as obtained in the Assay.
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

Change to read:

• PROCEDURE

All solutions containing methylene blue ▲should▲ (USP 1-Aug-2022) be freshly prepared prior to analysis.

Solution A: 0.1% [trifluoroacetic acid](#) in [water](#)

Solution B: [Acetonitrile](#)

Diluent: *Solution A* and *Solution B* (70:30)

Mobile phase: *Solution A* and *Solution B* (75:25)

Standard solution: 100 µg/mL of [USP Methylene Blue RS](#) in *Diluent*

Sample solution: Nominally 100 µg/mL of methylene blue in *Diluent*, from Injection

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 246 nm. For *Identification A*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 10-cm; 3.5-µm packing [L11](#)

Temperatures

Autosampler: 5°

Column: 30°

Flow rate: 1 mL/min

Injection volume: 5 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of methylene blue ▲trihydrate▲ (USP 1-Aug-2022) ($C_{16}H_{18}ClN_3S \cdot 3H_2O$) in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of methylene blue from the *Sample solution*

r_S = peak response of methylene blue from the *Standard solution*

C_S = concentration of [USP Methylene Blue RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of methylene blue in the *Sample solution* (µg/mL)

M_{r1} = molecular weight of methylene blue trihydrate, 373.90

M_{r2} = molecular weight of methylene blue anhydrous, 319.85

Acceptance criteria: 95.0%–105.0%

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

Solution A, Solution B, Diluent, and Chromatographic system: Proceed as directed in the Assay.

Mobile phase: ▲ (USP 1-Aug-2022) See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	80	20
5	80	20
25	30	70
32	30	70

System suitability solution: 1 mg/mL of [USP Methylene Blue RS](#) and 0.03 mg/mL of [USP Azure B RS](#) in *Diluent*

Standard solution: 1 µg/mL of [USP Methylene Blue RS](#) in *Diluent*

Sensitivity solution: 0.25 µg/mL of [USP Methylene Blue RS](#) in *Diluent* from the *Standard solution*

Sample solution: Nominally ▲ (USP 1-Aug-2022) 500 µg/mL of methylene blue ▲ (USP 1-Aug-2022) in *Diluent* from Injection

System suitability

Samples: *System suitability solution, Standard solution, and Sensitivity solution*

Suitability requirements

Resolution: NLT 3.5 between the methylene blue and azure B peaks, *System suitability solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution and Sample solution*

Calculate the percentage of each specified ▲ degradation product ▲ (USP 1-Aug-2022) in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each ▲ specified degradation product ▲ (USP 1-Aug-2022) from the *Sample solution*

r_S = peak response of methylene blue from the *Standard solution*

C_S = concentration of [USP Methylene Blue RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of methylene blue in the *Sample solution* (µg/mL)

Calculate the percentage of any unspecified ▲ degradation product ▲ (USP 1-Aug-2022) in the portion of Injection taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response of any unspecified ▲ degradation product ▲ (USP 1-Aug-2022) from the *Sample solution*

r_T = sum of all the peak responses from the *Sample solution*

Acceptance criteria: See [Table 2](#). ▲ The reporting threshold is ▲ (USP 1-Aug-2022) 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Azure C ^a ▲ (USP 1-Aug-2022)	0.32	0.20
Azure A ^b ▲ (USP 1-Aug-2022)	0.52	0.20
Azure B ^c	0.82	3.0
Methylene blue	1.00	—
Any unspecified ▲degradation product▲ (USP 1-Aug-2022)	—	0.20
Total ▲degradation products ^d ▲ (USP 1-Aug-2022)	—	5.0

^a 3-Amino-7-(methylamino)phenothiazin-5-ium chloride.

^b 3-Amino-7-(dimethylamino)phenothiazin-5-ium chloride.

^c Azure B is quantitated using the test for *Limit of Azure B* and is included in the table for identification purposes.

^d Total degradation products include the sum of the results from the tests for *Organic Impurities* and *Limit of Azure B*.

Change to read:

• LIMIT OF AZURE B

Diluent, Mobile phase, Sample solution, and Chromatographic system: Proceed as directed in the Assay.

Standard solution: 3 µg/mL of [USP Methylene Blue RS](#) in *Diluent*

System suitability: Proceed as directed in the Assay using the *Standard solution* from the Assay.

[NOTE—The relative retention times for azure B and methylene blue are 0.70 and 1.00, respectively.]

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of azure B in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of azure B from the *Sample solution*

r_S = peak response of methylene blue from the *Standard solution*

C_S = concentration of [USP Methylene Blue RS](#) in the *Standard solution* ▲(µg/mL)▲ (USP 1-Aug-2022)

C_U = nominal concentration of methylene blue in the *Sample solution* ▲(µg/mL)▲ (USP 1-Aug-2022)

Acceptance criteria: NMT 3.0%

SPECIFIC TESTS

• [pH \(791\)](#): 3.0–4.5

Change to read:

• [BACTERIAL ENDOTOXINS TEST \(85\)](#): ▲Meets the requirements▲ (USP 1-Aug-2022)

Add the following:

▲• [STERILITY TESTS \(71\)](#): Meets the requirements▲ (USP 1-Aug-2022)

• **OTHER REQUIREMENTS:** It meets the requirements in [Injections and Implanted Drug Products \(1\)](#).

ADDITIONAL REQUIREMENTS

Change to read:

• **PACKAGING AND STORAGE:** Preserve in single-dose containers, preferably of Type I glass. Store at ▲controlled▲ (USP 1-Aug-2022) room temperature, protected from light. Do not refrigerate or freeze.

Add the following:

▲• **LABELING:** The label to indicate for "Intravenous use only".▲ (USP 1-Aug-2022)

• [USP REFERENCE STANDARDS \(11\)](#).

[USP Azure B RS](#)
3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride.
C₁₅H₁₆ClN₃S 305.82
[USP Methylene Blue RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METHYLENE BLUE INJECTION	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(6)

Current DocID: GUID-D6113BEF-A38D-44F1-A69C-AFFCBB9CEFCF_4_en-US

DOI: <https://doi.org/10.31003/USPNF.M52490.04.01>

DOI ref: [eka19](#)

OFFICIAL